
    
      Postsurgical inflammation is an inevitable condition after cataract surgery. The use of
      non-steroidal anti-inflammatory drugs is a safe option for treating ocular inflammation.

      This is a phase II randomized double-blind clinical trial. The aim is to compare and to
      evaluate efficacy and safety of two ophthalmic solutions in patients post
      phacoemulsification. Patients will be randomized to receive either PRO-155 or Nevanac for 60
      days.
    
  